By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Immunomedics, Inc. 

300 American Road

Morris Plains  New Jersey  07950-2450  U.S.A.
Phone: 201-605-8200 Fax: 973-605-8282



Company News
Immunomedics (IMMU) Announces Agreements To Exchange Approximately $80.0 Million Of Its 4.75% Convertible Senior Notes Due 2020 For Common Stock 9/15/2017 8:21:26 AM
Immunomedics (IMMU) Presents Interim Phase II Results With Sacituzumab Govitecan (IMMU-132) In Patients With Pretreated Metastatic Urothelial Cancer 9/11/2017 11:28:18 AM
Immunomedics (IMMU) Announces Publication Of Phase II Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy As A Single Agent In Patients With Metastatic Colorectal Cancer 8/21/2017 8:49:40 AM
Immunomedics (IMMU) Announces Fiscal 2017 Results And Strategic Developments; Reiterates Guidance On BLA Submission Timeline 8/17/2017 10:22:44 AM
Immunomedics (IMMU) Announces Conference Call And Webcast For Fourth Quarter And Fiscal Year 2017 Results 8/8/2017 1:40:03 PM
Published Results From Clinical Trials Demonstrate Therapeutic Potential For Immunomedics (IMMU)’ Sacituzumab Govitecan (IMMU-132) In The Treatment Of Metastatic Solid Cancers 7/10/2017 9:04:17 AM
Immunomedics (IMMU) Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 5/11/2017 1:18:22 PM
Immunomedics (IMMU) Announces Conference Call And Webcast For Third Quarter Fiscal 2017 Results 5/10/2017 9:04:49 AM
Immunomedics (IMMU) Rise Too Much As Seattle Genetics (SGEN) Deal Terminated? 5/8/2017 7:06:05 AM
Immunomedics (IMMU) Delivers Business Updates, Announces Private Placement Offering And Outlines Strategic Steps To Drive Stockholder Value 5/5/2017 8:31:47 AM